A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
This study is for people with a common type of bladder cancer that hasn't spread into the muscle, called non-muscle invasive bladder cancer. We are testing a new treatment called TAR-210 to see if it's more effective than standard chemotherapy treatments like Gemcitabine or MMC (Mitomycin C). The main goal is to find out if TAR-210 can keep the cancer from coming back for longer. This is a Phase 3 study, meaning it's one of the final steps before a new treatment might become widely available. We are also looking if the cancer has a specific change (mutation or fusion) in a gene called FGFR which might make the new treatment more effective.
Auf einen Blick
Worum geht es in dieser Studie?
This clinical trial is designed for people who have a specific type of bladder cancer known as Non-Muscle Invasive Bladder Neoplasms. This means the cancer cells are found in the lining of the bladder but haven't grown into the deeper muscle layer. It's a common form of bladder cancer, and treatments usually aim to remove the cancer and prevent it from returning.
The study is comparing two different approaches. One group of participants will receive a new treatment called TAR-210. The other group will receive standard chemotherapy treatments that are usually put directly into the bladder, such as Gemcitabine or MMC. The main reason for doing this study is to see which treatment is better at stopping the cancer from coming back after it's been removed.
Researchers are particularly interested in how long people stay 'disease-free,' meaning how long it takes before the cancer reappears. They are also looking at whether having a specific genetic change, called an 'FGFR mutation or fusion,' affects how well TAR-210 works. This information could help doctors decide if TAR-210 is a good option for certain patients in the future.
Wichtige Erkenntnisse
- This study compares a new bladder cancer treatment (TAR-210) with standard chemotherapy.
- It's for a common type of bladder cancer that hasn't spread to the bladder muscle.
- The main goal is to see which treatment keeps the cancer away for longer.
- You would undergo regular bladder checks and assessments if you join.
- Having a specific genetic change (FGFR mutation or fusion) is important for eligibility.
- Die Teilnahme ist freiwillig, und Sie können jederzeit zurücktreten.
Wer könnte berechtigt sein?
To join this study, you must have a recent diagnosis (within the last 3 months) of a specific type of non-muscle invasive bladder cancer. This includes certain types of low-grade tumours, especially if they have some risk factors, such as multiple tumours, a larger single tumour (3cm or more), or if the cancer has come back quickly or often after previous treatment. For some parts of the study, your doctor will need to decide that MMC (a common chemotherapy drug) would be the usual treatment for you.
Another important requirement is that your cancer cells, or your urine, must show a specific genetic change called an 'FGFR mutation or fusion.' This will be checked by special tests. You must also be generally well enough to take part in the study activities and be willing to undergo regular bladder examinations (cystoscopies) and any necessary additional surgeries to remove cancer if it returns.
There are also reasons why you might not be able to join. For example, if you have known allergies to certain medicines or substances (we can't list them all here), this study might not be right for you. Your study doctor will discuss all the specific details to make sure you're a good fit for the trial.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Have you been diagnosed with non-muscle invasive bladder cancer recently?
- Does your cancer have specific risk factors, like recurring often?
- Has your doctor confirmed that your cancer shows an 'FGFR mutation or fusion'?
- Are you able and willing to have regular bladder examinations (cystoscopies)?
- Sind Sie im Allgemeinen gesund und aktiv genug für tägliche Aufgaben?
Was beinhaltet die Teilnahme?
If you join this study, you will be randomly assigned to either receive the new treatment, TAR-210, or one of the standard chemotherapy treatments (Gemcitabine or MMC) put directly into your bladder. This means you won't get to choose which treatment you receive. You will need to have several check-ups, including regular bladder examinations (cystoscopies) throughout the study and potentially a procedure called a TURBT (Transurethral Resection of Bladder Tumor) if the cancer comes back or gets worse, to assess your condition.
The overall duration of your involvement in the study will vary, but it will involve ongoing monitoring to see how well the treatment is working and to keep track of your health. Your study team will explain the full schedule of visits, treatments, and follow-up appointments, so you know exactly what to expect from start to finish.
Potenzielle Risiken und Vorteile
Locations (193)
- Arkansas UrologyVerifizierte PostleitzahlLittle Rock, Vereinigte Staaten· Abgeschlossen
- Genesis Research LLCVerifizierte PostleitzahlLos Alamitos, Vereinigte Staaten· Aktiv, aber nicht rekrutierend
- USC Norris Comprehensive Cancer CenterVerifizierte PostleitzahlLos Angeles, Vereinigte Staaten· Aktiv, aber nicht rekrutierend
- University of California Irvine Medical CenterVerifizierte PostleitzahlOrange, Vereinigte Staaten· Aktiv, aber nicht rekrutierend
- Om Research LLCVerifizierte PostleitzahlSan Diego, Vereinigte Staaten· Aktiv, aber nicht rekrutierend
- Genesis Research LLC 1Verifizierte PostleitzahlSherman Oaks, United States· Abgeschlossen
- University of Colorado Cancer Center Anschultz Cancer PavilionVerifizierte PostleitzahlAurora, Vereinigte Staaten· Abgeschlossen
- Colorado Clinical ResearchVerifizierte PostleitzahlLakewood, Vereinigte Staaten· Aktiv, aber nicht rekrutierend
- Moffitt KrebszentrumVerifizierte PostleitzahlTampa, Vereinigte Staaten· Aktiv, aber nicht rekrutierend
- Northwestern UniversitätVerifizierte PostleitzahlChicago, Vereinigte Staaten· Abgeschlossen
- First UrologyVerifizierte PostleitzahlJeffersonville, United States· Abgeschlossen
- Wichita Urology GroupVerifizierte PostleitzahlWichita, Vereinigte Staaten· Aktiv, aber nicht rekrutierend
Häufige Fragen
What is Non-Muscle Invasive Bladder Neoplasms?
It's a type of bladder cancer where the cancer cells are only in the bladder's inner lining and haven't spread to the deeper muscle.
What does 'Phase 3' mean for a drug trial?
Phase 3 means this is one of the final stages of testing. It compares the new treatment with existing ones to prove it's safe and effective before it can be widely used.
What is TAR-210?
TAR-210 is a new treatment being tested for bladder cancer. The study aims to see how well it works compared to current standard treatments.
What is an 'FGFR mutation or fusion'?
It's a specific change in a gene (called FGFR) that can happen in some bladder cancers. Researchers are studying if this change helps predict if TAR-210 will work well.
Werde ich meine Behandlung auswählen können?
No, you will be randomly assigned to either receive TAR-210 or a standard chemotherapy treatment. This is to ensure the study results are fair and unbiased.
Wie Sie mehr erfahren können
Studienkontakt
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Interessiert daran, teilzunehmen?
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.